Chesley Taft & Associates’s AstraZeneca AZN Stock Holding History

Chesley Taft & Associates’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15.4M	Buy	81,276 +2,474	+3%	+$465K	0.6%	45
2026 Q1	$15.5M	Buy	78,802 +2,427	+3%	+$468K	0.65%	46
2025 Q4	$14M	Buy	76,375 +12,992	+20%	+$2.28M	0.55%	47
2025 Q3	$9.73M	Sell	63,383 -2,835	-4%	-$429K	0.41%	57
2025 Q2	$9.25M	Buy	66,218 +263	+0.4%	+$36.9K	0.41%	60
2025 Q1	$9.7M	Buy	65,955 +64,255	+3,780%	+$9.3M	0.47%	59
2024 Q4	$223K	Sell	1,700 -6,563	-79%	-$919K	0.01%	316
2024 Q3	$1.29M	Buy	+8,263	New	+$1.33M	0.06%	177

Other funds holding AZN

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

AAMU

AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

ASR Vermogensbeheer Utrecht, Netherlands $9.71B AUM 37.32% 1-Year Est. Return

MIF

Mediolanum International Funds Dublin 1, Ireland $11.7B AUM 47.18% 1-Year Est. Return

ZIC

ZWJ Investment Counsel Atlanta, Georgia $3.09B AUM 39.43% 1-Year Est. Return

AIM

Achmea Investment Management Zeist, Netherlands $4B AUM 31.99% 1-Year Est. Return

Chesley Taft & Associates's AZN Position: Q2 2026 in Review

Chesley Taft & Associates increased its AstraZeneca (AZN) stake by 3.1% in Q2 2026, buying an estimated $465K and bringing the position to 81,276 shares worth $15.4M. The position accounts for 0.6% of the portfolio, ranked #45.

Chesley Taft & Associates first reported a position in AZN in Q3 2024 and has held it in 8 quarters since. The position peaked at $15.5M in Q1 2026. 403 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Chesley Taft & Associates held 81,276 shares of AstraZeneca worth $15.4M as of Q2 2026.
Chesley Taft & Associates bought 2,474 AstraZeneca shares in Q2 2026, an estimated $465K.
AstraZeneca made up 0.6% of Chesley Taft & Associates's portfolio in Q2 2026, its #45 holding.
Chesley Taft & Associates first reported a position in AstraZeneca in Q3 2024 and has held it in 8 quarters since.
Chesley Taft & Associates's AstraZeneca position peaked at $15.5M in Q1 2026.
403 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Chesley Taft & Associates's 13F filing for Q2 2026, filed 8 Jul 2026.